Table 1.
Main characteristics and results of the eligible studies
| Study (year) | Tumor type | Ethnicity | Number of patients | Method | HR estimate | HR (95% CI) |
|---|---|---|---|---|---|---|
| Lv et al6 (2012) | Non-small-cell lung cancer | Asian | 80 | IHC | Survival curve | 2.49 (1.51–4.08) |
| Zhao et al8 (2012) | Hepatocellular carcinoma | Asian | 198 | IHC | Reported | 2.456 (1.234–3.932) |
| Ding et al7 (2013) | Colon cancer | Asian | 108 | IHC | Survival curve | 1.74 (1.03–2.94) |
| Yu et al9 (2013) | Esophageal cancer | Asian | 134 | IHC | Survival curve | 2.42 (1.43–4.07) |
| Lin et al10 (2014) | Esophageal cancer | Asian | 135 | IHC | Reported | 1.645 (1.182–2.5) |
| Derr et al12 (2014) | Breast cancer | Caucasian | 261 | IHC | Reported | 1.182 (0.935–1.495) |
| Chen et al13 (2014) | Esophageal cancer | Asian | 103 | IHC | Reported | 1.34 (0.69–2.6) |
| Miura et al14 (2014) | Human melanomas | Asian | 63 | IHC | Available data | 0.689 (0.083–5.715) |
| Yuan et al11 (2015) | Tongue cancer | Asian | 67 | IHC | Reported | 3.908 (1.238–12.339) |
Abbreviation: IHC, immunohistochemistry.